NCT07084246Active, not recruiting
Evaluation of the Effectiveness and Safety of Rozetel Tablet in Patients After PCI: A Multi-Center Observational Study
A Multi-center, Prospective, Non-intervention, Observational Study to Evaluate the Effectiveness and Safety of the Rozetel Tablet in Patients Who Had Undergone Percutaneous Coronary Intervention(PCI)
Source: ClinicalTrials.gov · Last updated 24 Jul 2025
Brief summary (registry, in English)
The purpose of this study is to evaluate the effectiveness and safety of the investigational drug on blood pressure and LDL cholesterol control during the observation period in patients who have undergone percutaneous coronary intervention (PCI) in actual clinical practice.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 1563 (actual)
- First submitted
- 16 Jul 2025
- Start date
- 7 Jun 2023
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- GC Biopharma Corp
- Diseases
- High blood pressure
- NCT number
- NCT07084246
What you commit to
- Study type: Observational
- Participants enrolled: 1563
- From 7 Jun 2023 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- 1\. Individuals who fall under the contraindications for administration according to the approved indications of the investigational product.
- 2\. Individuals who have a history of receiving the investigational product prior to participation in this study.
- 3\. Individuals whom the investigator deems unsuitable for participation in this observational study for any other reason.
Who the study is looking for
- 1\. Adults aged 19 years and older, both male and female. 2. Patients who have undergone percutaneous coronary intervention (PCI) and are receiving antihypertensive and dyslipidemia-related medications.
- 3\. Individuals who require the administration of the investigational product based on the investigator's medical judgment in accordance with approved indications.
- 4\. Individuals who can understand the information provided to them and are able to voluntarily sign the informed consent form.
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| GC Biopharma Coordinator of this site? Confirm its status | Yŏngin | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.